This article is more than 5 years old. Information may no longer be current.
Pass-through status reinstated for Omidria
Click Here to Manage Email Alerts
Cataract surgery drug Omidria received a 2-year reinstatement of pass-through status by the CMS, according to an Omeros press release.
The extension goes into effect Oct. 1. Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution) was one of several drugs used during procedures on Medicare Part B fee-for-service patients to receive an extension of pass-through reimbursement status.
The 2-year extension was passed into law in March as part of the Consolidated Appropriations Act of 2018. It will remain in effect until Oct. 1, 2020, according to the release.
Omidria is the only FDA-approved product for use during cataract surgery or IOL replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain.